Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2023 Feb 20;14:1155631. doi: 10.3389/fphar.2023.1155631

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Yu-Yang Liu 1,, Yi-Yang Qu 1,, Shang Wang 1,, Ci-Jun Luo 1, Hong-Ling Qiu 1, Hui-Ting Li 1, Ping Yuan 1, Lan Wang 1, Jin-Ling Li 1,2,*, Rong Jiang 1,*, Rui Zhang 2,*
PMCID: PMC9987690  PMID: 36891269

In the published article, there was an error.

A correction has been made to the conclusions of the abstract on page one. This sentence previously stated:

“PAH patients benefit from PDE-5is compared to riociguat, including in hemodynamic parameters, 6MWD, WHO-FC and biomarkers.”

The corrected sentence appears below:

“Compared to PDE5i, PAH patients benefit more from riociguat in hemodynamics, 6MWD, WHO-FC and biomarkers.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES